Nephros (NASDAQ:NEPH) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Nephros (NASDAQ:NEPHFree Report) to a strong-buy rating in a research note issued to investors on Saturday morning.

A number of other research analysts also recently commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a research report on Wednesday, October 8th. Maxim Group raised their target price on shares of Nephros from $4.50 to $6.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Read Our Latest Report on Nephros

Nephros Stock Performance

NASDAQ NEPH opened at $4.89 on Friday. The company has a market capitalization of $51.83 million, a price-to-earnings ratio of 40.75 and a beta of 1.32. The company’s 50-day simple moving average is $4.44 and its two-hundred day simple moving average is $3.47. Nephros has a one year low of $1.36 and a one year high of $5.98.

Nephros (NASDAQ:NEPHGet Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.04. The business had revenue of $4.40 million for the quarter, compared to the consensus estimate of $3.60 million. Nephros had a net margin of 7.95% and a return on equity of 14.89%.

Institutional Trading of Nephros

An institutional investor recently raised its position in Nephros stock. Geode Capital Management LLC raised its holdings in shares of Nephros Inc. (NASDAQ:NEPHFree Report) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 93,187 shares of the company’s stock after acquiring an additional 2,898 shares during the period. Geode Capital Management LLC owned approximately 0.88% of Nephros worth $381,000 at the end of the most recent quarter. Institutional investors own 41.10% of the company’s stock.

Nephros Company Profile

(Get Free Report)

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

See Also

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.